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The epidemiology of infectious diseases must consider a number of aspects of the 
disease along with its control and prevention, as these will ultimately alter disease 
incidence, trends and distribution within a population. For many infectious diseases, the 
greatest medical tool available to combat them is vaccination. Historically, the UK has 
successfully controlled invasive meningococcal disease through vaccination. As a 
result, the majority of disease seen in today ’s epidemiological landscape is caused by a 
previously non-preventable form. Monitoring the epidemiology of invasive 
meningococcal disease relies on strong surveillance systems which in turn, allow for the 
evaluation of vaccination programmes. An understanding of the relationship between a 
vaccination programme and its effect on the epidemiology of the targeted disease is 
vital for assessing the success of a programme and gives insight into how these 
programmes may be improved. 
 
This thesis presents eight studies, presented in three sections, that used 
epidemiological data to demonstrate the success of the national infant MenB 
vaccination programme in England. The studies presented have provided baseline 
estimates of the burden of invasive meningococcal disease (IMD) and the predicted 
strain coverage of the 4CMenB vaccine against circulating strains in England prior to 
the vaccine’s national introduction in September 2015. These studies also provided the 
first ever estimates of 4CMenB’s vaccine effectiveness at a reduced vaccination 
schedule, to that used for licensure, along with the impact on MenB disease in the 
group with the highest incidence of disease, children under the age of five, who were 
targeted with the vaccine. Further, these studies looked at the epidemiology and trends 
of disease in vulnerable populations in England, highlighting the markedly increased risk 
in a young person on long term complement inhibitor therapy and raising awareness of 
the increased risk in cases who initially present with a less common presentation and its 
implications for the public health and clinical management of these cases. Finally, these 
studies explored cases of IMD in pregnant women in England over a four-year period 






finding of a significantly decreased risk of IMD in pregnant women compared to non-
pregnant women of a similar age. 
 
The combined findings of these studies show the success of the first nationally funded 
4CMenB immunisation programme and its subsequent effects on the epidemiology of 



























































Understanding the epidemiology of communicable diseases encompasses multiple 
factors rooted in its aetiology. Understanding how patterns of how a pathogen acts, how 
the human body responds, and the pathogen’s behavior once it has successfully 
infected a population are all required to successfully control and prevent its spread. 
High quality, multifaceted surveillance underpins all of those aspects and is pivotal in 
implementing disease control programmes. Invasive meningococcal disease (IMD) is a 
severe disease which is marked by its rapid and aggressive nature which can be life-
threatening and many survivors are left with long-term complications which include 
amputations, deafness and neurological complications. While IMD is rare in the UK, the 
highest burden falls on children aged under five years, particularly in infants, with a 
second peak in incidence in adolescents and older adults aged 65 and older. In the UK 
the highest burden of IMD is due to a type of meningococci that until 2013 was 
previously unpreventable. A novel multicomponent vaccine, 4CMenB, prevents this form 
of disease and was licensed on immunogenicity studies alone. In September 2015, the 








Known scientifically as Neisseria meningitidis, the meningococcus is the organism 
responsible for invasive meningococcal disease (IMD). N. meningitidis is a member of 
the Neisseriaceae bacterial family, is a Gram-negative ß-proteobacterium, and is a 
fastidious facultative anaerobe, meaning that it can grow with or without the presence of 
oxygen. It is exclusively found in humans where its main reservoir is the 
nasopharyngeal tract and is typically harmless (Van Deuren et al., 2000). As a result, it 
is often considered an ‘accidental pathogen’ that harbors a number of characteristics 






The polysaccharide capsule 
 
Meningococci can be encapsulated or unencapsulated, although the vast majority of 
bacteria responsible for causing invasive disease, when they enter normally sterile sites 
such as blood or cerebrospinal fluid (CSF), are encapsulated. The bacterial capsule is 
composed of polysaccharides, and those associated with the main bacterial type 
associated with invasive meningococcal disease (IMD) are usually composed of sialic 
acid derivatives. The exception to this are MenA and MenX organisms whose capsules 
are comprised of repeating units of N-acetyl-mannosamine-1-phosphate (Swartley et 
al., 1998). Neu5Ac is the most common form of sialic acid in humans and plays an 
important role in intracellular/intramolecular recognition (Varki et al., 2017). Neu5Ac is 
incorporated into the capsule of the meningococcus and this molecular mimicry allows it 
to be less detectable to the host’s immune system (Rouphael and Stephens, 2012). 
One example can be seen in the MenB capsule, which contains a form of sialic acid (α 
(2-8)-linked homopolymer) which is identical to human fetal neuronal cell adhesion 
molecules (Rouphael and Stephens, 2012). This makes it a challenging to target the 
MenB capsule in vaccines as it runs the risk of eliciting an autoimmune response. 
 
The biochemistry of the capsule is the foundation for the categorisation and 
nomenclature of the N. meningitidis bacterial species which is referred to as the 
serogroup. Based on antigenic differences in the polysaccharide capsule, there are 12 
serogroups, A, B, C, E, H, I, K, L, X, W, Y and Z. Half of these (A, B, C, W, X, and Y) 
are responsible for the majority of IMD, with prevalence of each varying greatly by 
geographic region. 
 
The polysaccharide capsules of B and C organisms are composed of entirely sialic acid 
with MenB and MenC having α 2>8 and α 2>9 linkages respectively (Table 1). MenW 
contains repeating units of sialic acid and D-galactose while MenY is comprised of sialic 
acid and D-glucose. MenA and MenX capsules do not contain sialic acid and instead 
are comprised of N-acetylmannosamine-1-phosphate and N-acetylglucosamine-1-
phosphate respectively (Table 1). Thus, the polysaccharide capsule helps to inhibit 
phagocytosis and provides resistance to antibody/complement-mediated killing 
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(Kugelberg et al., 2008) and thus is essential for bacterial survival in blood and is also 




Table 1: Comparison of important meningococcal serogroups and their capsule st ructures  
 






















































































































As N. meningitidis is a commensal bacterium it is commonly carried asymptomatically, 
in the mucosa of the nasopharynx, by approximately 10 % of the population (Caugant 
and Maiden, 2009). The rates of bacteria carriage increase in certain conditions, such 
as in those who have chronic upper respiratory conditions and those who smoke with 
peak carriage rates seen in adolescence. To be able to cause invasive disease, the 
bacterium must survive in the bloodstream and spread. In order for the meningococcus 
to survive, a number of different methods may be used to evade the host’s immune 
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system. The ability for meningococci to cause disease relies on a combination of genes 
or allelic variants of genes (Tinsley and Nassif, 2001). There have been and continue to 
be multiple attempts to identify genetic elements of the bacteria that are associated with 
invasive disease (Tinsley and Nassif, 1996; Bart et al., 2000). To date the region in the 
bacteria which encodes the ability to synthesise the polysaccharide capsule remains the 
principal determinant of virulence (Caugant and Maiden, 2009). During pathogenesis, 
the expression of the polysaccharide capsule undergoes genetic regulation (Pizza and 
Rappuoli, 2015). The meningococcal capsule is essential for survival in the blood as it 
prevents phagocytosis and aids in the evasion of the host’s immune response. For this 
reason, the genes responsible for capsular synthesis, termed cps are typically 
upregulated when invading the bloodstream and downregulated or lost entirely during 
asymptomatic carriage (Pizza and Rappuoli, 2015). This, along with a number of other 
factors result in meningococci having a pathogenic potential with the ability to pass 
through epithelial cells and enter the blood stream where they may survive and multiply 
(Taha et al., 2002; Caugant and Maiden, 2009). The bacterial capsule offers protection 
from the host’s immune system as it is poorly immunogenic and along with other 
surface structures of the bacteria, such as those involved in attachment to host cells or 
those that can stimulate the release of inflammatory mediators can lead to septic shock 
(Van Amersfoort et al., 2003). 
 
Many meningococci do not have capsular loci, cannot generate a capsule and are not 
associated with invasive disease in healthy individuals as they are killed by complement 
(Jódar et al., 2002). It is known that meningococci can switch their capsular expression 
in the nasopharynx (Ala’Aldeen et al., 2000) and thus a hypervirulent MenC strain has 
the potential to become a hypervirulent MenW strain thereby potentially evading 




Invasive meningococcal disease occurs when the meningococcus enters an otherwise 
sterile site in the body (such as blood, CSF, joint fluids) which can result in 




pneumonia, arthritis, epiglottitis and pericarditis (Harfi et al., 2012). Although rare, IMD 
is a life-threatening disease and one that is feared due to its sudden onset and rapid 
deterioration. Case fatality rates of up to 80% have been seen in untreated cases 
(Flexner, 1913) and 8-15% in those receiving treatment (ECDC, 2017b). Survivors of 
IMD may also experience marked morbidity with 12-20% suffering from clinical 
sequelae such as deafness, brain damage and amputations (Lucas et al., 2016). 
 
 




IMD is typically a disease of healthy individuals, although the exact reasons as to why 
some people develop more severe disease than others are still not fully understood. 
Recent studies using genome wide association studies (GWAS) (Davila et al., 2010) 
have identified aspects within hosts that may contribute to an increased susceptibility to 
IMD. One interaction which has proven to be important in the pathogenesis of IMD is 
that between the meningococcus and the complement system (Ladhani et al., 2019) In 
immunocompetent individuals, their complement system acts as a first line of defense 
against IMD, as it is essential in lysing the bacteria in the blood (Lewis and Ram, 2014; 
Ladhani et al., 2019). Therefore, in individuals with defects in various components of the 
complement system; such as in the alternative pathway (properdin and factor D), the 
terminal pathway (C5 to C9) (Rosain et al., 2017) as well as those with autosomal 
recessive terminal complement pathway deficiencies are all at an increased risk for IMD 
(Figueroa et al., 1993). 
 
In addition to inherited complement deficiencies, there are also medical conditions and 
treatments, particularly those for paroxysmal nocturnal haemoglobinuria (PHN) and 
atypical haemolytic uraemic syndrome (aHUS), that require complement inhibitors 
which in turn can result in either acquired or secondary complement deficiency 
(Figueroa and Densen, 1991). Individuals with these disorders are rare (0.03% of the 
general population) but are associated with a 7000 to 10,000-fold higher risk of IMD, 
with 50-60% experiencing ≥1 IMD episode (Figueroa and Densen, 1991). Other 
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immunocompromised individuals such as those with human immunodeficiency virus 
(HIV) have also been associated with an increased risk for IMD (Simmons et al., 2015). 
A family history of IMD has been shown to be associated with an increased risk which 
would suggest there may be genetic factors that may be important for susceptibility to 
this disease (Olea et al., 2017). A case-control study showed genetic polymorphisms 
may effect susceptibility to IMD (Domingo et al., 2002) while population-based methods, 
such as genome-wide association studies (GWAS) have shown genetic variation in the 
complement factor H (CFH) is associated with susceptibility to IMD (Davila et al., 2010). 
GWAS studies of meningococcal cases has shown that variation in the regulation of 
complement activity plays a role in determining which individuals will get invasive 
disease versus those who will be asymptomatic carriers (Davila et al., 2010; Martinón-




The environmental factors that contribute to a higher chance of developing IMD are 
those associated with settings that increase the chance of an individual encountering 
and acquiring meningococci. These settings include crowding in both living and social 
situations, mixing of adolescents in university halls of residence (Mandal et al., 2017), 
crowded conditions associated with mass gatherings such as Hajj, the annual Islamic 
pilgrimage to Mecca (Yezli, 2018) and other international mass gatherings, such as 
music festivals, scout jamborees (Kanai et al., 2017) and more recently, funerals (Patel 
et al., 2017). Seasonal changes are also highly associated with IMD incidence. In 
temperate climates, such as in England and mainland Europe, peak incidences are 
seen in the winter months. This could be for a number of reasons, including an 
increased tendency to spend time indoors along with a simultaneous increased 
incidence for viral infections, where influenza in particular has been shown as a risk 
factor for IMD(Cartwright et al., 1991; Jacobs et al., 2014). Conversely, the dry season 
is often the peak of IMD incidence in sub-Saharan Africa where dust and low humidity 












Classification by serogroup is extremely useful and often the first method of 
summarising IMD epidemiology. However, a deeper understanding of IMD epidemiology 
and potential methods of prevention through vaccination requires knowledge beyond 
serogroup (Harrison et al., 2009). Newer molecular approaches to IMD classification 
accompany the traditional serological methods to help scientists better understand 




Since the mid-1990s PCR-based diagnostics have been more widely used to identify 
patients with meningococcal disease as well as other bacterial infections (Corless et al., 
2001). Since its introduction this diagnostic method has substantially increased IMD 
burden estimates (Gray et al., 2006). A negative aspect of PCR is the absence of a 
bacterial isolate for phenotyping. Phenotyping allows for a finer level of classification, 
beyond capsular group and subtype. However, there are further genotypic 
characterisations possible from PCR samples. 
 
Multilocus sequence typing 
 
Since its introduction in 1998 multilocus sequence typing (MLST) has become more 
widely used for the molecular characterisation of N. meningitidis. MLST is a nucleotide 
sequence-based approach that can be applied to many bacterial pathogens and is 
conducted by sequencing bacteria’s DNA on seven portions of the DNA known as 
‘housekeeping genes’. The reason housekeeping genes are the focus of this method is 
because these genes are not considered to be under any selective pressure. This 
results in allelic profiles of isolates that can be compared to a large central database 
and used to determine the genetic lineage of N. meningitidis (Maiden et al., 1998). 
Another advantage of MLST is that allelic profiles can be obtained from clinical material. 
The seven housekeeping loci can be amplified in these samples directly from blood or 
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CSF from IMD cases by polymerase chain reaction (PCR) (Urwin and Maiden, 2003). 
This means isolates can be characterised even if they cannot be cultured from clinical 
specimens (Urwin and Maiden, 2003). MLST has widely replaced multilocus enzyme 
electrophoresis (MLEE) as the primary method for determining genetic lineage(Harrison 
et al., 2009). MLST targets the housekeeping genes to classify meningococci into 
sequence types (ST) based on changes in these genes. Meningococci are highly 
variable, but often the same ST can be found in different capsular groups, for example 
ST-11 clonal complex (cc11; also known as the ET-37 complex and lineage 11) are 
hyperinvasive and may express serogroups C or W and, less frequently, B or Y 
(Lucidarme et al., 2015). Beyond this, meningococci are often also classified by clonal 
complexes (cc), bacterial lineages, which consist of groups of related STs. A clonal 
complex includes several lineages of highly related isolates (clones) (Taha, 2002). Most 
invasive meningococcal isolates belong to a limited number of ccs, which correspond to 
the hyperinvasive lineages (Lucidarme et al., 2015). The ability of a few hyper virulent 
meningococcal strains to cause the majority of disease globally is still not fully 
understood. 
 
Whole genome sequencing 
 
Whole genome sequencing (WGS) is newer approach of typing that offers an even 
higher resolution of characterisation, distinguishing meningococci on up to 2200 genes 
(Jolley et al., 2012). This also allows WGS to distinguish between very closely related 
meningococci and track the evolution of different strains (Whaley et al., 2018). In 
England, WGS has been routinely carried out on all bacterial isolates, which are those 
cases confirmed by culture where a live organism was isolated from a sterile site. Like 
MLST, databases have been developed to contain global genetic data from 
meningococcal WGS which enables the ability to map the distribution of isolates from 






Some countries use other non-culture based approaches to supplement cultures. These 
methods include Latex agglutination, a laboratory method used to check for certain 
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or antigens in a clinical specimens (typically blood or CSF). The sample is mixed with 
latex beads, coated with a specific antibody or antigen and if the suspected substance 
is present, the latex beads will clump together (agglutinate) (Latex agglutination test: 
 
MedlinePlus Medical Encyclopedia, n.d.). This allows for serogroup identification and is 
a rapid diagnostic with results taking from 15 minutes to an hour (Sobanski et al., 2001). 
 
4. Epidemiology of IMD 
 
IMD is a global disease and varies by serogroup, serotype, serosubtype, cc, 
geographical region and time. Patterns of IMD are unpredictable differing widely by age 
serogroup and severity. The majority of IMD is due to clonal complexes of N. 
meningitidis that harbor the propensity to emerge, spread and cause infection 
worldwide. MenC and MenW account for substantial proportions of IMD in most of 
Africa and Latin America, while MenB is the predominant serogroup across Europe, 
North America and the Western Pacific (Booy et al., 2018). While natural fluctuations in 
disease do occur, such trends are also influenced by public health interventions, 
including prevention and control through vaccination which will inevitably cause 
additional shifts in IMD epidemiology. 
 
Understanding the local epidemiology, trends over time and impact of meningococcal 
vaccination programmes is important not only in understanding how vaccination 
programmes affect disease patterns but also to identify knowledge gaps and potential 
for further reductions in disease burden through additional preventive strategies as new 
more effective and higher valent meningococcal vaccines become available. 
 
Epidemiology of IMD in England prior to September 2015 
 
Trends in IMD across England and Wales have been consistently reported since the 
early 1990s. Data from the national reference laboratory between 1993/94 and 2003/04 
reported an average annual incidence of 3.8/100,000 population (median: 3.8/100,000; 
range: 2.3-5.4/100,000) (Gray et al., 2006). This also captured the start of an increase 
in MenC disease in 1995/96 with continued momentum and associated increase in 
mortality through 1999/00. This finding lead to widespread introduction of the 




vaccine in November 1999 for all individuals aged less than 25 years of age. The 
introduction of the MCC vaccine was based on serological criteria alone, without the 
direct evidence of vaccine efficacy which set a precedent for other meningococcal 
vaccines (Miller et al., 2001). Between 1993/94-2000/01 a continued increase in MenB 
incidence was observed along with their diversity in phenotypes where it accounted for 
the majority of disease but at that time was unpreventable. Since 2009/10, the UK has 
experienced a year-on-year increase in MenW disease due to rapid expansion of a 
single endemic hyper-virulent strain belonging to sequence type 11 clonal complex (cc) 
(Ladhani et al., 2015). Consequently, the quadrivalent MenACWY conjugate vaccine 
was introduced in adolescents aged 13-18 beginning August 2015 (Campbell et al., 
2015). It was recently reported that serum samples from children immunized with a 
meningococcal serogroup B vaccine (4CMenB) demonstrated potent serum bactericidal 
antibody activity against the hypervirulent Neisseria meningitidis serogroup W strain 
belonging to the sequence type (ST) 11 clonal complex, circulating in England (Ladhani 




5. Meningococcal vaccines 
 
Vaccination is the key method of IMD prevention with various vaccines and vaccination 
strategies developed over the years. Vaccination aims to protect those who are 
vaccinated against IMD when exposed as well as reducing the acquisition, carriage and 




Polysaccharide vaccines containing the polysaccharide capsule of single or multiple 
meningococcal serogroups have been available for more than 40 years. While they 
remain ineffective in young children, they have been proven to be immunogenic and 
safe in older children and adults. Most polysaccharides are thymus-independent 
antigens which do not require T-cells to induce an immune response (Mond et al., 
1995). This often results in them being unable to induce memory cells in neonates and 




booster doses (Ali et al., 2014). Polysaccharide vaccines are still used, mainly in lower-




Protein-conjugate vaccines, on the other hand, use a carrier protein to present the 
meningococcal capsular polysaccharide to the immune system, in a manner that 
induces a T-cell mediated response (Ali et al., 2014). As a result, these vaccines are 
immunogenic from birth, induce immune memory, protect for a longer duration and 
provide a booster response with subsequent doses (Borrow et al., 2017). In addition to 
providing direct protection in vaccinated individuals, protein-conjugate vaccines also 
prevent the acquisition of bacterial carriage, thus disrupting transmission and inducing 
indirect (herd) protection across the population (Trotter and Maiden, 2009). Currently, 
both polysaccharide and protein-conjugate vaccines are available against serogroups A, 
C, W and Y; since these vaccines contain capsular antigens, they do not provide cross-
protection against other meningococcal serogroups. Similar protein-conjugate vaccines 
against MenB have been difficult to develop because the MenB capsular polysaccharide 
contains components which are similar to human foetal neuronal cells and are, 
therefore, poorly immunogenic with the potential to induce autoimmune antibodies (Tan 
et al., 2010). 
 
Outer membrane vesicle vaccines 
 
Meningococcal outer membrane proteins have been used for over 20 years in millions 
of vaccine doses. They have been used as a carrier protein in Haemophilus influenzae 
type b (Hib) polysaccharide conjugate vaccine and as vesicle vaccine formulations 
against meningococcal disease (Holst et al., 2009). In Gram negative bacteria, outer 
membrane vesicles (OMVs) play a key role in the interaction and communication 
between the host and pathogen (Vernikos and Medini, 2014). OMVs are involved in 
overall disease progression, since they act as vehicles for the secretion of bacterial 
proteins and lipids which allows them to play a role in colonization, modification of the 
host’s immune response and delivery of virulence factors into host cells (Kuehn and 
Kesty, 2005). Research into the use of OMV based vaccines to control specific 
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outbreaks began in the 1970s and since then there have been three independently 
developed vaccines for the use against regional MenB outbreaks in Cuba (1987-1989), 
Norway (1988-1991) and New Zealand (2004-2008), with estimated vaccine 
effectiveness of 83%, 87% and 73% respectively (Sierra et al., 1991; Rosenqvist et al., 
1995; Arnold et al., 2011). The compromise with OMV vaccines is the tradeoff between 
their coverage and effectiveness. Mounted immune responses by these vaccines are 
largely strain specific and directed against the immunodominant PorA in the vaccine. An 
exception to the typical homologous coverage was observed with two OMV vaccines. 
Cuba was the first to develop and successfully test the first effective MenB OMV 
vaccine (VA-MENGOC-BC) OMV vaccine that was used to control an outbreak of MenB 
(B4:P1.15) in both Cuba and Brazil, where it proved effective against both the outbreak 
strain and other circulating strains of MenB (Sierra et al., 1991; de Moraes et al., 1992). 
Similarly, the New Zealand OMV vaccine (MeNZBâ) seemed to be cross-protection 
between strains and regional evidence showed an estimated 54% effectiveness against 
heterologous MenB strains as well as 56% effectiveness against circulating non-MenB 




Reverse vaccinology and 4CMenB 
 
Reverse vaccinology uses a genomic, rather than cellular approach to vaccine 
development. Vaccines are classically developed using a pathogenic strain in vitro to 
produce a live attenuated strain that is harmless to the host but preserves its ability to 
elicit an immune response. Other approaches have also used antigens to develop 
subunit vaccines. These methods have been highly successful for a number of 
pathogens but remain unfeasible in cases where components of the pathogen, like 
MenB, that provoke immune responses are very similar to components in host tissues 
(Vernikos and Medini, 2014). Thus, reverse vaccinology has been applied successfully 
to pathogens that have otherwise been pervicacious. The first example of successful 







The 4CMenB vaccine 
 
This first success in reverse vaccinology identified three recombinant proteins—factor H 
binding protein (fHbp) variant 1.1, neisserial heparin-binding antigen (NHBA) peptide 2, 
and neisserial adhesin A (NadA) variant 3. These three recombinant proteins were 
included in 4CMenB, together with outer membrane vesicles containing the porin PorA 
(P1.4) from a New Zealand outbreak strain used in MeNZB®. 
 
These proteins are each involved in different processes of IMD pathogenesis. 
Factor H binding protein (fHbp) is a surface-exposed lipoprotein. Its function is to 
help the meningococcus evade alternative complement pathway-mediated killing 
by binding activate factor H onto the cell surface of the meningococcus (Madico et 
al., 2006) 
Previously referred to as GNA2132, the neisseria heparin binding antigen (NHBA) is an 
important protective antigen of N. meningitidis. NHBA binds heparin and heparin 
sulphate which is thought to play a role in the evasion of complement-mediated 
bacterial lysis (Serruto et al., 2010). Neisserial adhesion A (NadA) is also a surface 
exposed protein that is believed to have a role in meningococcal adhesion to epithelial 
cells of the nasopharynx. Unlike capsular polysaccharides, which tend to be expressed 
abundantly and are antigenically relatively uniform in invasive meningococci, surface 
proteins can be sparse and antigenically diverse. This also means that the vaccine will 
not protect against all MenB strains.The ability of 4CMenB to protect against serogroup 
B meningococcal strains and the breadth of protection depends on the degree of 
surface expression and the extent to which vaccine induced antibodies recognise and 
bind to these proteins (Donnelly et al., 2010). To evaluate vaccine strain coverage, the 
Meningococcal Antigen Typing System (MATS) was created by the vaccine 
manufacturer. MATS was a novel laboratory testing method to be used on invasive 
isolates. It aimed to determine whether in the isolate, each antigen was sufficiently 
expressed and if the isolates antigen(s) was similar enough to the antigen in the vaccine 








6. Surveillance of IMD 
 
Disease surveillance systems are the means by which the prevalence, incidence and 
distribution of IMD is ascertained. Differences in IMD epidemiology can only be fully 
understood in the context of a region’s surveillance system and the associated 
strengths and weaknesses. The ideal system would have laboratory-based surveillance 
that confirms clinically suspected cases of IMD to inform national surveillance. Most 
surveillance systems rely on specimens from normally sterile sites (CSF, blood and 
other normally sterile bodily fluids) since specimens from non-sterile sites like the 
pharynx are not used to confirm invasive disease as a large proportion of the population 
asymptomatically carry N. meningitidis in this part of the body. 
 
Incidence of IMD varies globally by region and in many areas of the world, the gold-
standard method of active surveillance and laboratory confirmation and strain 
characterisation is not possible. Thus, combinations of different surveillance systems 
and diagnostic methods are used and vary by and across country, making comparison 
and ascertainment of true IMD incidence difficult. 
 
The following sections focus on specific areas of surveillance that are used to derive 




In addition to case ascertainment, population-based surveillance is ideal as it enables 
disease incidence to be determined (Harrison et al., 2009). This can be achieved 
through sentinel surveillance which uses nominated reporting units with a high 
probability of seeing cases of the disease in question (WHO | Sentinel Surveillance, 
n.d.). This can be useful if the population base is known and the chosen centres are 
thought to be representative of the general population. However, if this is not the case 
the incidence of IMD cases can be skewed or under-representative. However, when the 
chosen sites are applicable to the general population, sentinel surveillance can be very 





Active or passive surveillance 
 
Another feature of surveillance systems is whether they are active or passive. Passive 
surveillance often involves reporting of IMD cases, usually required by law, by 
healthcare providers and/or laboratories. These reports are then collected by local 
health authorities. Passive surveillance is advantageous as it occurs continuously and 
requires few resources but relies on a strong public health infrastructure and would 
potentially not capture those without access to health care. Conversely, active 
surveillance involves health authorities regularly contacting each entity required to 
report cases and eliciting reports (Harrison et al., 2009). The main difference between 
these methods is the sensitivity of surveillance (proportion of notifiable cases that are 








Notification of clinically diagnosed cases of IMD, by a registered medical practitioner, is 
a statutory requirement in England and has been since the early 1990s where all cases 
of IMD require public health management. This is to ensure contacts of the case are 
identified and offered antibiotic chemoprophylaxis and vaccination (where appropriate) 
(PHE guidance 2019). This management is undertaken by the PHE Health Protection 
Teams (HPT) in an area local to the case. Medical practitioners responsible for the case 
notify their local HPT who then report this to PHE. As a result, there is a national record 
of notified cases captured on HPZone, a national web-based case management system 
used by local HPTs as a method to rapidly record public health events and actions. 
These notifications hold information on gender, age in years, regional location and often 
provide some insight into the clinical presentation of the case. 
 
Laboratory confirmation of cases 
 
When a high proportion of clinically suspected cases are investigated, microbiologically, 




level. This data is both sensitive and specific and circumvents some of the uncertainty 
around diagnosis which is present for many diseases but especially IMD where initial 
presentations can often be non-specific(Gray et al., 2006). In England, the PHE 
Meningococcal Reference Unit (MRU) provides a national reference service for IMD 
confirmation and characterisation of invasive meningococci (both culture and non-
culture). The MRU also provides free non-culture PCR confirmation of meningococcal 
diagnosis (including genogroup and genosubtype analysis) for clinical specimens from 
patients with suspected IMD, that are routinely submitted by the National Health Service 
(NHS) hospitals in England (PHE enhanced surveillance plan, 2019). Since 1999, all 
confirmed cases of IMD are referred to the PHE immunisation team where they are then 
followed up to confirm vaccination history, travel history, country of birth and any 
underlying medical conditions. Using laboratory confirmed cases to ascertain IMD 
incidence in England is a method that has proven high case ascertainment (Ladhani et 
al, 2015). Since July 2010, all invasive meningococcal isolates sent to the MRU are also 
whole genome sequenced. 
 
Laboratory surveillance of MenB IMD 
 
Invasive MenB disease is defined as an individual with isolation of MenB or positive 
capsular group B specific PCR from a normally sterile site. The impact of 4CMenB is 
monitored using the Meningococcal Antigen Typing MATS is not yet validated for use 
against non-MenB isolates. 
 
The definition of an isolate with a positive MATS assay result (“MATS positive”) and 
therefore potential coverage by 4CMenB is a MenB strain with a relative potency 
(versus that of a reference strain) of at least one vaccine protein (fHbp, NadA, NHBA) 
above the positive bactericidal threshold (PBT) and/or determination of a P1.4 PorA 
subtype by sequencing of VR2 and/or by serosubtyping. 
 
In accordance with a new study (Muzzi et al., 2019) for non-culture MenB cases, a PorA 
genosubtype of P1.4 and /or fHbp genotype for peptides 1, 2, 4, 14, 15, 37, 89, 90, 110, 
144, 224, 232, 245, 249, 252, or 510 are considered likely to be covered by the vaccine 




Vaccine coverage data 
 
PHE routinely collects data on vaccine uptake using Collection of Vaccination Evaluated 
Rapidly (COVER), a mandated routine coverage collection which was established in 
1987 COVER standardises on collecting data for children at 12 months, 24 months and 
5 years of age. This is done through the collation of data from Child Health Information 
Systems (CHIS). Local authority data from CHIS are extracted to and submitted to PHE 
where they are collated and analysed to report on childhood vaccination levels in 
England. 
 
Data on deaths 
 
PHE has access to electronic death registration records provided by the Office for 
National Statistics (ONS). These are data where IMD, meningococcal septicaemia, 
meningococcal meningitis or other meningococcal related causes have been identified 
as the cause of death. ONS data is linked with laboratory data to determine casual 
capsular group of the infecting meningococci. Additionally, the NHS Personal 
Demographics Service (PDS) is also used to ascertain whether or not a patient has died 
within a reasonable period of disease onset (typically 28 days). 
 
Enhanced surveillance in England 
 
In 2013, PHE enhanced the laboratory surveillance of IMD by collecting clinical data 
using postal questionnaires to general practitioners (GPs) of laboratory confirmed IMD 
cases diagnosed since 01 January 2011. These questionnaires aimed to capture 
information on comorbidities, risk factors, clinical presentation, intensive care admission 
(ICU) and outcomes. Enhanced surveillance was revised to include an opportunity to 
collect vaccination history and extended to follow-up all laboratory confirmed cases of 
IMD from September 2015. Instead of requesting this information from GPs, enhanced 
surveillance from September 2015 involved the PHE immunisation team liaising with 
HPTs for the completion of epidemiological surveillance forms. In addition to these 
surveillance forms, detailed clinical questionnaires were designed for completion by the 
responsible hospital consultant for all cases of confirmed IMD in children less than 5 
years of age. This questionnaire aimed to gather information on length of hospital stay, 
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clinical investigations including blood and cerebrospinal fluid test, imaging (CT scan, 
MRI or ultrasound), outcome and sequelae. Changes in the surveillance of IMD were 
made to align with the introduction of a new MenB infant vaccination programme and a 
MenACWY vaccination programme for teenagers. 
 
 
From 1st of September 2015, all infants born on or after the 01 May 2015 were 
offered the vaccine at a reduced 2+1 schedule with two catch-up cohorts (Table 1). 
 
Table 2: Definition of catch-up and routine cohorts eligible for Bexsero® under the 
national immunisation programme 
  
Vaccination Cohort Birth dates Vaccination schedule 
   
 May 2015 4 and 12-13 months (1+1) 
Catch-up cohort   
June 2015 3,4 and 12-13 months (2+1)  
   
Routine cohort on or after 01 July 2015 2,4 and 12-13 months (2+1) 




This thesis presents eight studies to demonstrate the effect of the 4CMenB infant 
vaccination programme on the epidemiology of MenB disease in England and show that 
this work contributes the first real-world evidence of the vaccine’s impact and 
effectiveness. This is split into three chapters in the form of: six observational studies, 
one case report, and one literature review from work carried out between 2015 and 
2020 in England. 
 
 
Chapter one begins with an overview of IMD, meningococcal vaccines, the development 
of vaccines against group B meningococcal disease, risk factors for disease and the 
types and roles of national surveillance in monitoring disease and vaccination 




area of IMD epidemiology prior to the introduction of the new vaccine and how this 
provided a baseline for studies that came after its implementation. Chapter three is 
comprised of two studies that explain the epidemiological experience with the MenB 
vaccine in England, 10 months and 3 years after its introduction, and its effect and 
effectiveness in vaccinated populations. Chapter four contains three studies that 
examine IMD in vulnerable populations as what implications these risk factors have for 
the management of these cases. Finally, chapter five discusses the impact of the 
findings in the studies presented as well as potential for further work on group B 




















































1. Invasive meningococcal disease epidemiology and predicted strain 
coverage of 4CMenB prior to its introduction in the national 








Three publications have been selected that use national surveillance data to establish 
baselines, both epidemiological and molecular, against which the impact of the 
meningococcal group B vaccination programme will be measured in future. These 
studies updated and built on earlier epidemiological summaries conducted in England 
and Wales (Gray et al., 2006; Ladhani et al., 2012), along with strain coverage 
estimates (Vogel et al., 2013)and the potential of 4CMenB to protect against non-group 
B meningococcal strains (Ladhani et al., 2016). 
 
3.1. Study 1 
 
Epidemiology, clinical presentation, risk factors, intensive care admission and 
outcomes of invasive meningococcal disease in England, 2010-2015. Vaccine 
(2018) 
 
Sydel R. Parikh, Helen Campbell, Stephen J. Gray, Kazim Beebeejaun, Sonia Ribeiro, 
Ray Borrow, Mary E. Ramsay, Shamez N. Ladhani 
 
3.1.1. Study 1 Aim 
 
This study aimed to summarise the epidemiology and capsular group distribution of IMD 
in England along with linked information on risk factors, clinical presentation and 
outcomes of disease over four calendar years. The study aimed to update national and 





3.1.2. Study 1 Summary 
 
National surveillance data on laboratory confirmed cases of IMD along with capsular 
group, diagnostic method and regional information were used in conjunction with ONS 
data on population estimates to determine IMD incidence by age, capsular group and 
geographical region. Information from enhanced surveillance questionnaires sent to 
GPs included data on comorbidities, risk factors, clinical presentation, intensive care 
admission (ICU) and outcomes. Incomplete or missing information in the questionnaires 
was followed-up by telephoning the GP, contacting the patient’s hospital clinician or 
requesting additional information from the local PHE health protection team (HPT), 
which maintains records of all suspected and confirmed IMD cases for public health 
management of cases and close contact and for monitoring outbreaks. If needed, 
additional information was sought from HPZone, electronic ONS death registration 
records were linked with laboratory data. Dates of death were confirmed using the NHS 
PDS and only deaths occurring within 28 days of receipt of sample were included. 
Clinical data were presented for cases diagnosed between January 2011and July 2015. 
These data were analysed descriptively and logistic regression was used where 




3.1.3. Study 1 Results 
 
This study provided updated and detailed insight into the burden of IMD in England 
between 2011-2015. This paper showed that IMD epidemiology in England was still 
similar to mainland Europe with declining incidences in both overall IMD and IMD due to 
MenB. The large cohort of cases allowed for the first time, the description of clinical 
presentations, risk factors, severity and outcomes of IMD by age and capsular group. 
England has one of the highest disease incidences in Europe and the resulting case 
numbers allow for a more accurate assessment of disease characteristics. Enhanced 
follow-up was achieved for all 3411 cases diagnosed in England during 01 January 
2011 and 30 June 2015. Using this data, this study was able to show, for the first time, a 
low prevalence of known risk factors among IMD cases. This paper also presented data 




interesting to note from this work that MenY cases became more prevalent with 
increasing age, as did atypical clinical presentations and diagnosis with only a cultured 
specimen. 
 
3.1.4. Contribution to Study 1 
 
Jointly conceived the project, solely carried out the data collation and analysis and 
wrote the first draft of the manuscript. 
 
3.2. Study 2 
 
 
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB 
vaccine with corresponding regional distribution and clinical characteristics in 
England, Wales, and Northern Ireland, 2007–08 and 2014–15: a qualitative and 
quantitative assessment. Lancet Infectious Diseases (2017) 
 
Sydel R. Parikh, Lynne Newbold, Stephanie Slater, Maria Stella, Monica Moschioni, Jay 
Lucidarme, Rosita De Paola, Maria Giuliani, Laura Serino, Stephen J Gray, Stephen A 
Clark, Jamie Findlow, Mariagrazia Pizza, Mary E Ramsay, Shamez N Ladhani, Ray 
Borrow 
 
3.2.1. Study 2 Aim 
 
This paper updated the predicted coverage of 4CMenB against circulating MenB strains 
in the UK, using MenB strains from two epidemiological years, 2007/2008 and 
2014/2015. MATS coverage estimates were assessed for 2014-15 MenB isolates in the 
UK and then compared to corresponding 2007-08 data on MATS coverage estimates 
and regional distribution. An additional feature of this study was that it assessed age 
distribution, clinical characteristics and outcomes of IMD in patients with MATS-positive 
and MATS-negative MenB isolates in England. This estimate of coverage served as a 
baseline against which future estimates would be based following the introduction of the 
infant 4CMenB programme that commenced in September 2015 (data in this paper is to 
the end of June 2015). 
 
3.2.2. Study 2 Summary 
 
Invasive serogroup B meningococcal isolates from cases in England, Wales, and 
Northern Ireland were characterised genotypically by multilocus sequence typing (Jolley 
and Maiden, 2010) and each of the four main 4CMenB antigens. This was carried out 
  
24 
for two epidemiological years 2007-2008 and 2014-2015. Clinical characteristics, risk 
factors, and outcomes were assessed according to MATS coverage for 2014–15 
English cases. In order to properly assess vaccine coverage estimates, it was 
necessary to determine the genetic constitution of the MenB isolates. This was 
conducted by characterising the genotypes of 2014–15 isolates with data extracted from 
the Meningitis Research Foundation’s Meningococcus Genome Library was used since 
it contained the genome sequences for all English, Welsh, and Northern Irish invasive 
isolates received by the Public Health England Meningococcal Reference Unit since 
July, 2010. MATS data were generated for both epidemiological years (2007–08 and 
2014–15) using the same methods described previously (Donnelly et al., 2010; Plikaytis 
et al., 2012; Domnich et al., 2015). PorA subtypes were determined by phenotyping. 
MATS predicted strain coverage was defined as the proportion of serogroup B 
meningococcal isolates with MATS relative potency greater than the positive 
bactericidal thresholds for one or more antigen or the presence of PorA (P1.4). 
 
In 2014–15, 165 of 251 (66%; 95% CI 52–80) meningococcal group B isolates were 
estimated by MATS to be covered by 4CMenB, compared with 391 of 535 (73%; 95% 
CI 57–87) in 2007–08. The proportion of MATS-positive isolates with one vaccine 
antigen increased from 23% (122 of 535) in 2007–08 to 31% (78 of 251) in 2014–15, 
whereas the proportion with more than one antigen fell from 50% (269 of 535) to 35% 
(87 of 251). This effect reflected changes in the circulating strains, particularly the ST-
269 clonal complex strains. 
 
In a logistic regression model, MATS positivity was associated with a 1.95-fold 
increased risk (95% CI 1.02–3.76; p=0.017) of severe invasive meningococcal disease 
(intensive care admission, death, or both), independent of age, sex, underlying 












3.2.3. Study 2 New knowledge gained 
 
 
This study updated the predicted 4CMenB strain coverage for England, Wales and 
Northern Ireland prior to the introduction of the vaccine into the national immunisation 
programme in the UK. MATS coverage increased with age, varied by geographical 
region, and was associated with more severe disease. MATS coverage was highest for 
individuals older than 5 years for both 2007-08 (77%) and 2014-15 (70%). In 2014-15, 
MATS coverage as well as the number of antigens covered, were mostly lower across 
all age groups when compared with coverage estimates from 2007-08. Of particular 
interest, in 2014-15, over a third (37%) of MenB isolates in infants were MATS-negative 
and a further 30% were only covered by one vaccine antigen. MATS-positivity was also 
found to be associated with a significant 1.95-fold increased risk of severe IMD 
(intensive care admission, death or both) which was independent of sex, age, 
underlying comorbidity or clinical presentation. 
 
This study demonstrated that predicted strain coverage of the 4CMenB vaccine, against 
circulating MenB strains in England and Wales, fell between the two observed 
epidemiological years. This is important to note before the introduction of the vaccine 
into the national infant immunisation programme, especially in light of a very low 
estimated coverage among infants in England. 
 
3.3. Study 3 
 
 
Meningococcal Group W Disease in Infants and Potential Prevention by 
Vaccination Emerging Infectious Diseases (2016) 
 
Sydel R. Parikh, Helen Campbell, Kazim Beebeejaun, Sonia Ribeiro, Steve J. Gray, 
Ray Borrow, Mary E. Ramsay, Shamez N. Ladhani 
 
3.3.1. Study 3 Aim 
 
This study aimed to assess the historical trends of MenW disease in infants in England 
in the three most recent epidemiological years (2012-13 to 2014-15) prior to the 
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introduction of 4CMenB. This was aimed to establish the picture of MenW disease in 
infants at that time and postulate the number of cases that may be prevented by MenB 
vaccination, given published evidence (Ladhani et al. 2016) on the potential of 4CMenB 
to also protect against the hyper-virulent ST-11 MenW strain, which is also prevalent in 
England and for which no vaccine is licensed for infants 
 
3.3.2. Study 3 Summary 
 
National enhanced surveillance data on laboratory confirmed cases of IMD were used 
to retrospectively summarise the epidemiology of MenW disease in England across all 
ages between, the epidemiological years 1998-99 and 2014-15. MenW cases occurring 
between 2012-13 and 2014-15 in those aged <1 year were looked at by age in months 
(≤ 11 months). Laboratory data for cases in this group, confirmed by culture, were 
analyzed phenotypically in order to identify MenW:2a strains, a surrogate phenotypic 
marker for the hypervirulent ST-11 MenW strain. 
 
3.3.3. Study 3 Results 
 
This study established long term trends of MenW incidence and phenotypic distribution 
in England over a 17-year period. A total of 176 MenW cases occurred during this time 
across all age groups where the number of cases peaked during 2000-01 (n=28) due to 
a national outbreak associated with the Hajj pilgrimage but this soon declined after 
mandatory vaccination for pilgrims was initiated. MenW cases in infants began to 
increase again beginning in 2012-13 (n=4), rising to 12 in 2013-14 and in 2014-15 
MenW (n=21) accounted for 16.5% of all cases of IMD in infants (n=127). Breakdown of 
MenW incidence by age in months, before 1 year of age, showed a peak at 4 months of 
age which remained high until the first birthday. 
 
Phenotypic characterisation can only be performed on cases confirmed by culture and 
thus it could not be ascertained for cases confirmed by PCR only. Between 2012-13 
and 2014-15 a total of 25 (67.5%) of 37 MenW cases in infants were confirmed by 
culture of which nearly half (n=18; 49%) were characterised as MenW:2a, a surrogate 
phenotypic marker for the hypervirulent ST-11 MenW strain. Data on age distribution 




introduction of the 4CMenB vaccine at 2 and 4 months of age, while from mid-2016 the 
booster will be available for children aged 1 year of age and could work to protect 
toddlers for whom MenW cases were also increasing. 
 
3.3.4. Study 3 New Knowledge gained 
 
 
This is the first study that established a baseline of the phenotypic epidemiology of 
MenW cases in infants and it was demonstrated that 4CMenB could protect against 
circulating MenW:cc11 strains which is important as MenW causes the greatest number 















































Published papers presented in Chapter Two 
 
Study 1: Epidemiology, clinical presentation, risk factors, intensive care 
admission and outcomes of invasive meningococcal disease in 





































































































































































































































































































































































































Study 2: Meningococcal serogroup B strain coverage of the 
multicomponent 4CMenB vaccine with corresponding regional 
distribution and clinical characteristics in England, Wales and Northern 
Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. 











































































































































































































































































































































































































































































































































































































Study 3: Meningococcal Group W Disease in Infants and Potential 









































































































































































































2. Impact and effectiveness of the 4CMenB vaccine in the national infant 
immunisation programme in England 
 
 
3.1. Study 4 
 
 
Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine 
against group B meningococcal disease in England: a national observational 
cohort study The Lancet (2016) 
 
Sydel R Parikh, Nick J Andrews, Kazim Beebeejaun, Helen Campbell, Sonia Ribeiro, 
Charlotte Ward, Joanne M White, Ray Borrow, Mary E Ramsay, Shamez N Ladhani 
 
3.1.1. Study 4 Aim 
 
This study aimed to generate data on early estimates of the impact of the 4CMenB 
vaccine against MenB disease in infants and also the vaccine effectiveness (VE) 
against MenB disease in immunized individuals in England after the first 10 months of 
investigation of the vaccine into the national programme. 
 
3.1.2. Study 4 Summary 
 
Data from the enhanced national surveillance of IMD was used to ascertain the number 
of confirmed MenB cases in vaccine eligible infants. This was followed up with local 
PHE health protection teams, general practitioners and hospital clinicians to collect 
demographic data, vaccination history, clinical presentation and determine the 
outcomes of disease. For cases diagnosed between 01 September, 2015 and 30 June, 
2016, vaccine effectiveness was assessed using the screening method (Farrington, 
1993). VE was calculated for at least one dose and two doses based on specific ages 
including a comparator group (Table 3) and allowing for 2 weeks (14 days) for the 
development of an adequate immune response. Population vaccine coverage in 




coverage data for some national immunisation programmes. Since ImmForm does not 
collect individual dates of birth or vaccination, vaccine coverage for comparators was 
estimated by adjusting the 6-month ImmForm coverage using actual dates of birth and 
dates of vaccination for about 36,000 infants receiving their first dose and about 26,000 
receiving their second dose as supplied by five Child Health Information Systems 
(CHIS). This was performed in order to control for any confounding by age and time, for 
each MenB case. 
 















Definition of age used 
 
77 days (11 weeks of age) 
 
133 days (17 weeks of age) 
 
 
For each MenB case: all infants in England 
who were born in the same month at an 
age in days exactly 14 days younger than 






Vaccine impact was estimated for vaccine-eligible MenB cases (born on or after 01 May 
2015 aged 10 weeks or older and diagnosed between 01 September 2015 and 30 June 
2016). Incidence rate ratios (IRRs) were estimated for vaccine eligible cases compared 
 
to cases diagnosed in the equivalent time period during the 4 years before vaccine 
introduction. 
 
3.1.3. Study 4 Results 
 
This study provided the first evidence of protection against group B meningococcal 
 
disease conferred by the novel multicomponent 4CMenB vaccine in infants. In England, 
vaccine coverage was shown to be high in all eligible cohorts, reaching 95.5% for one 




vaccine eligible infants (born on or after 01 May 2015 aged ≥ 10 weeks at diagnosis) 
and vaccination history was obtained for all cases. Two dose vaccine effectiveness of 
82.9% (CI 24.1-95.2) against all MenB disease was equivalent to 94.2% against the 
highest predicted MenB strain coverage estimate of 88% (Frosi et al., 2013). Compared 
to the period prior to vaccine introduction, there was a 50% IRR reduction in MenB 
cases in the vaccine eligible cohort (37 cases vs 74 cases; IRR 0.50 [CI 0.36-0.71]; 
p=0.0001) which was irrespective of the infants’ vaccination status or predicted strain 
coverage. A non-significant 14% reduction was also observed in the unvaccinated 
cohort. However, when adjusting for this 14% disease reduction in the unvaccinated 
cohort, it was estimated that there was a 42% reduction (relative IRR 0.58 [CI 0.40-
0.85]; p=0.005) in the vaccine eligible cohort. 
 
3.1.4. Study 4 New knowledge gained 
 
 
This study provided the first evidence of protection against MenB disease as conferred 
by the 4CMenB vaccine in infants. These results showed a significant reduction in 
cases of MenB among vaccine-eligible infants within 10 months of the vaccine’s 
introduction in England. This study also showed that although the vaccine was licensed 
using a three-dose priming schedule in infancy, short-term VE against MenB disease 


























3.2. Study 5 
 
 
Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England 
The New England Journal of Medicine (2020) 
 
Shamez N Ladhani, Nick Andrews, Sydel R Parikh, Helen Campbell, Joanne White, 
Michael Edelstein, Xillian Bai, Jay Lucidarme, Ray Borrow, Mary E Ramsay 
 
3.2.1. Study 5 Aim 
 
This study used data from the enhanced national surveillance of IMD to evaluate the 
effect and effectiveness of 4CMenB in relation to invasive meningococcal group B 
disease in infants and children at 1 year of age and 2 years of age after the first 3 years 
of the national immunisation program in England. 
 
3.2.2. Study 5 Summary 
 
 
The methods in this study were carried out as described in Study 4 using data on 
vaccine coverage in England routinely collected through primary care and child health 
information systems. The following adaptations were made: In addition to reporting the 
percentage of eligible children who received two doses by 12 months and three doses 
by 18 months the timing of vaccination in days of age was calculated with the use of 
individual level data from local CHIS. The population effect was estimated with the use 
of national surveillance data on cases of laboratory confirmed MenB disease. Change in 
disease incidence was calculated from 4 pre-vaccine surveillance years (September 
through the following August) to the first 3 complete years after 4CMenB was 
introduced. The age groups used and their dose eligibilities during the study period 














Table 4: Summary of 4CMenB eligibility by epidemiological year as assessed in VE calculations  
 
   Epidem iologica l year  
       
Age 2015-16 2016-17  2017-18 
      
0-8 weeks  Too young to be vaccinated  
       
9-17 weeks      
       
18-51 weeks      
       
1 year      
       
2 years      
    
3-4 years Too old to have been vaccinated during the study period 
    
Part of  group eligible for 1 dose  Entire group eligible for 1 dose  
Part of  group eligible for 2 doses  Entire group eligible for 2 doses  
Part of  group eligible for 3 doses  Entire group eligible for 3 doses  





Since the 4CMenB vaccine did not protect against all meningococcal group B strains, 
the results of the MATS testing of isolates of invasive MenB cases obtained from 
vaccinated children were used to estimate the vaccine strain coverage of meningococci 
causing invasive disease in the different vaccinated cohorts. To estimate the vaccine 
effectiveness against vaccine-preventable meningococcal group B strains only, the 
vaccine effectiveness against all MenB (vaccine effectiveness all) was adjusted by 
applying the proportion (p) of culture-confirmed cases in vaccinated children that were 
MATS-positive to the total number of confirmed cases of MenB disease with MATS 
results in that cohort. 
 






This study provided the first estimates of vaccine effect and effectiveness for a complete 
2+1 schedule of 4CMenB using data from the first three years of the national 
immunisation programme. It also showed the sustained impact of the 4CMenB against 
MenB disease in infants. It was demonstrated that vaccine coverage remained high and 
data from 3 months of 2018 showed that 92.5% of children had completed the primary 
immunisations by their first birthday and 87.9% had received all three doses by 2 years. 
From 01 September 2015 to 31 August 2018, the incidence of MenB disease in England 
was significantly lower in vaccine-eligible cohorts than the expected incidence (63 
observed cases as compared with 253 expected cases; IRR, 0.25; [CI 0.19-0.36]) with a 
75% reduction in age groups that were fully eligible for vaccination. 
 
 
The adjusted VE against MenB disease was 52.7% (95% CI, −33.5 to 83.2) with a two-
dose priming schedule for infants and 59.1% (95% CI, −31.1 to 87.2) with a two-dose 
priming schedule plus a booster at 1 year). Although these VE dropped significantly 
from the early estimates after the first 10 months of the programme, during this 3-year 
study period, there were 169 cases of MenB disease in the vaccine- eligible cohorts, 





3.2.4. Study 5 New knowledge gained 
 
 
This study provided evidence that the 4CMenB program was associated with a 
continued positive effect against MenB disease in children in England. Further, the 
vaccine regime showed protection after three doses of the vaccine and this protection 
was sustained for at least 2 years. This evidence provided further support in favour of 
the effectiveness of a reduced 4CMenB vaccination schedule. This work provides 
information that will help other European countries since it provides evidence in favour 










Published papers presented in Chapter Three 
 
Study 4: Effectiveness and impact of a reduced infant schedule of 4CMenB 
vaccine against group B meningococcal disease in England: a national 









































































































































































































































































































































































































































































































































Study 5: Vaccination of Infants with Meningococcal Group B Vaccine 

























































































































































































































































































































































































































































































































































































































3.1. Study 6 
 
 
Meningococcal B Vaccine Failure with a Penicillin-Resistant Strain in a Young 
Adult on Long-Term Eculizumab Pediatrics (2017) 
 
Sydel R. Parikh, Jay Lucidarme, Coralie Bingham, Paul Warwicker, Tim Goodship, Ray 
Borrow, Shamez N. Ladhani 
 
3.1.1. Study 6 Aim 
 
This study aimed to describe a case of MenB disease due to a vaccine-preventable and 
penicillin-resistant strain in a fully immunized young adult on long-term complement 
inhibitor therapy and daily penicillin chemoprophylaxis. This paper was published with 
the aim of highlighting the difficulties in protecting patients on complement inhibitors 
against IMD. 
 
3.1.2. Study 6 Summary 
 
This case occurred in a 22-year old female who presented with very mild clinical 
presentations of fever, myalgia, sore throat and headache but no rash. Six months prior 
to this she was diagnosed with atypical haemolytic uremic syndrome (aHUS). She was 
placed on Eculizumab, which is a humanized monoclonal antibody that is a terminal 
complement inhibitor used as treatment for aHUS among other conditions. She had 
received group C meningococcal vaccine as part of the national programme in 2000 as 
well as the MenACWY vaccine. She received two doses of 4CMenB 1 month apart, 
following her aHUS diagnosis. It is difficult to interpret antibody titers for patients on 
eculizumab therapy as the drug inactivates the assay which uses exogenous human 





The infecting strain was shown to be fully preventable by the 4CMenB vaccine and was 
MATS positive on one antigen (NHBA). The minimum inhibitory concentration for the 
infecting strain was 0.5 mg/L for penicillin, which was double the threshold (0.25 mg/L) 
for penicillin resistance. Genomic analysis revealed the penA allele contained 3 
mutations associated with reduced penicillin sensitivity. Further comparisons within the 
PubMLST Neisseria database suggested a recombination event in an ancestral strain 
involving a putative gonococcal origin, a species associated with high rates of antibiotic 
resistance. 
 
3.1.3. Study 6 New knowledge gained 
 
This was the first case of 4CMenB vaccine failure on a patient receiving long-term 
eculizumab for aHUS. Although antibiotic resistance is very rare among meningococci 
(<5%) the case was infected with a strain with a high resistance to the antibiotic 
chemoprophylaxis she was on. This study served to highlight the importance of raising 
awareness of meningococcal disease in patients on eculizumab therapy, even when 
they are fully vaccinated and complying with prophylactic prescriptions. 
 
3.2. Study 7 
 
 
Primary meningococcal conjunctivitis: Summary of evidence for the clinical and 
public health management of cases and close contacts Journal of Infection (2019) 
 
Sydel R. Parikh, Helen Campbell, Sema Mandal, Mary E. Ramsay, Shamez N. Ladhani 
 
 
3.2.1. Study 7 Aim 
 
This study aimed to compile a review of the literature in order to provide robust 
evidence base to support recommendations for clinical and public health management 









3.2.2. Study 7 Summary 
 
A literature review was performed by searchin PubMed with the terms “Meningococcal”, 
“Conjunctivitis”, “primary meningococcal conjunctivitis” and any combination of 
“transmission” or “invasive disease”. Publication dates and languages were not limited. 
Ovid MEDLINE was searched via PubMed, EMBASE and NHS evidence (up to 
December 2018 week 3). The advanced search mode was used including the terms 
“Meningococcal”, “Conjunctivitis”, “primary meningococcal conjunctivitis” and any 
combination of “transmission” or “invasive disease” or “contacts” or “management” or 
“treatment”. Publication dates and languages were not limited. Case series and review 
articles that summarised previous publications on PMC were prioritized; the individual 
publications cited in such studies were not retrieved for additional review. 
 
Findings were summarised and sorted under three categories (with some articles in 
more than one category): 
 
1. Reports of IMD in patients with PMC 
 
2. Reports of IMD in close contacts of patients with PMC 
 
3. Reports of identical strains from PMC cases and screening of their 
household or close contacts in the absence of invasive disease 
 
3.2.3. Study 7 Results 
 
This study provided a clear report of the published data on PMC as it pertains to clinical 
and public health management of PMC cases and their close contacts. In the UK there 
is currently no consensus on this management. This review identified a 10-29% risk of 
IMD among PMC cases where systemic symptoms typically occur within two days 
(range: 3 hours to 4 days) (Reese, 1936; Odegaard, 1983; Barquet et al., 1990; Ellis et 
al., 1992; Stansfield et al., 1994). The review also highlighted that systemic antibiotic 
therapy for PMC was more effective than topical antibiotic therapy alone in the 
prevention of systemic disease (Newton and Wilson, 1977; Odegaard, 1983; Barquet et 
al., 1990). One study showed the risk of developing IMD was 19 times greater when 
cases were treated with topical antibiotics alone than if combined with systemic 





In light of these findings on the recommendation for antibiotic treatment of PMC cases 
this review raised three important questions and used the findings of the review to 
answer them as they pertain to the clinical and public health management of these 
cases: 
 
1. Unless a Gram stain of the conjunctival swab is performed quickly, the culture 
results of the bacterial eye swab may take at least 48 h to be reported. Therefore, 
should PMC cases initially treated with topical antibiotics alone be recalled for 
systemic antibiotics? 
2. Can children with PMC be treated with oral antibiotics when N. meningitidis is 
confirmed as the cause of the conjunctivitis? 
 
3. What is the duration of oral antibiotic treatment in an otherwise well child with PMC 
and no systemic symptoms? 
 
3.2.4. Study 7 New knowledge gained 
 
This study provided a clear report of the published data on PMC as it pertained to 
clinical and public health management of PMC cases and their close contacts. These 
findings provided support for current guidelines on the public health management of 
PMC cases in England and served to highlight the need for clearer, more up to date 
clinical recommendations for the treatment of PMC cases, in so much as to prevent 
progression to systemic disease. 
 
3.3. Study 8 
 
 
Lower risk of invasive meningococcal disease during pregnancy; national 
prospective surveillance in England, 2011-2014 British Journal of Obstetrics and 
Gynaecology (2019) 
 









3.3.1. Study 8 Aim 
 
The objective of this study was to estimate the risk of IMD in pregnant women 
compared with non-pregnant women and to describe the epidemiology, clinical 
characteristics and outcomes of IMD in pregnant women in England over a 4 year 
period. 
 
3.3.2. Study 8 Summary 
 
Enhanced national surveillance data was used in conjunction with short clinical 
questionnaires completed by general practitioners for laboratory confirmed cases of 
IMD in England since 01 January 2011. All laboratory confirmed cases of IMD in women 
of reproductive age (15-44 years) in England from 01 January 2011 to 31 December 
2014 (4 years) were included. Women in this cohort may have been eligible to receive 
the MenC conjugate vaccine but neither the 4CMenB nor the MenACWY vaccine were 
part of the national immunisation programme during this period. 
 
Information collected included comorbidities, clinical presentation, intensive care 
admission, and outcomes. Incomplete or missing information in the questionnaires was 
followed up by telephoning the GP, contacting the patient’s hospital clinician, or 
requesting additional information from the local PHE health protection team (HPT). If 
needed, additional information was sought from HPZone, and from the electronic death 
registration records from the Office for National Statistics (ONS). 
 
For fatal cases, the date of death was confirmed using the Personal Demographics 
Service (PDS). Online annual reports of the Confidential Enquiry into Maternal Deaths 
(CEMD, www.npeu.ox.ac.uk/mbrrace-uk/reports/confidential-enquiry- into-maternal-
deaths) were also accessed to identify any pregnancy-related deaths resulting from IMD 
during the surveillance period. The HPZone records for neonatal IMD cases confirmed 
during the surveillance period were checked for any mention of maternal illness during 







General population and maternity data (including total conceptions) for England was 
obtained from ONS. These were used for denominator populations (ONS Population 
Estimates Tool, accessed 02 May 2019; ONS Conception Statistics; accessed 02 May 
2019). 
 
Pregnant years were estimated as the product of the total number of conceptions 
between 2011 and 2014 and the maximum possible gestation period (9 months). This 
was then used to estimate non-pregnant years as the difference between the total 
female population aged 15–44 years and pregnant years. 
 
Demographic, clinical questionnaire and microbiological data were entered into a single 
Microsoft Access Database cleaned and de-duplicated before being imported into 
STATA 13.0 for analysis. Descriptive statistics were given for demographics and clinical 
characteristics of pregnant women with IMD. Core outcomes and estimates of IMD 
incidence rates with Poisson 95% confidence intervals for pregnant and non-pregnant 
women along with incidence rate ratios pregnant and non-pregnant women were also 
performed. 
 
3.3.3. Study 8 Results 
 
Between 2011 and 2014 (317,417,121 woman-years) there were 2980 cases of IMD in 
England. Clinical information was available for all 2980 cases. Of these, 1502 occurred 
in females across England over the four-year study period, 310 (20.6%) of which 
occurred in women of reproductive age (median age 20 years; Q1, 18 year; Q3, 28.5 
years). Among those of reproductive age, four women were reported pregnant at the 
time of IMD confirmation (1.3%). The four cases in otherwise healthy pregnant women 
were confirmed across all trimesters and all survived; one case in the first trimester had 
a septic miscarriage. The incidence of IMD was lower in pregnant than in non-pregnant 
women (0.16 compared with 0.76 per 100,000 pregnant and non-pregnant years, 








3.3.4. Study 8 New knowledge gained 
 
 
This study was the first to assess the risk of IMD in pregnancy and established that in 
our study population, pregnant women were nearly five times less likely to develop IMD 
compared to non-pregnant women, although the infection could still be severe. This 
knowledge could be used to alleviate worries among pregnant women and could also 





















































Published papers presented in Chapter Four 
 
Study 6: Meningococcal B Vaccine Failure with a Penicillin-Resistant 



































































































































































































































































Study 7: Primary meningococcal conjunctivitis: Summary of evidence for 
the clinical and public health management of cases and close contacts 






































































































































































































































































































































Study 8: Lower risk of invasive meningococcal disease during 
pregnancy; national prospective surveillance in England, 2011-2014 















































































































































































































































































































































































































These studies focus on the lead up to the introduction of 4CMenB into the national 
infant immunisation programme in September 2015 and the subsequent effect of the 
vaccine on the epidemiology of MenB disease. The epidemiology of IMD varies both 
regionally and over time, as different strains are introduced into the population and 
others abate naturally or through vaccination (Harrison et al., 2009). The epidemiology 
of IMD in England has been well documented and trends in disease have fluctuated due 
to both cyclical peaks and the implementation of successful vaccination programmes, 
namely the MCC programme that was implemented to combat an outbreak of MenC 
disease in the early 2000s (Miller et al., 2001). However, even during this MenC peak, 
MenB has been responsible for the majority of disease. 
 
3.1. Epidemiology and predicting 4CMenB strain coverage prior to 
vaccine introduction in England 
 
The studies in this chapter presented the epidemiology of overall IMD but focused on 
MenB cases in England along with the predicted strain coverage of the 4CMenB 
vaccine against circulating strains in England before it was included in the national 
infant immunisation programme. Study 1 established baseline trends in epidemiology, 
age distribution, clinical presentations and disease outcomes of IMD in England 
between 2011 and 2015. These findings showed that English epidemiology was similar 
to the rest of Europe, where the majority of IMD is caused by group B meningococci 
(ECDC, 2017b). The age distribution of IMD was also similar to that of other European 
(ECDC, 2017b) and North American countries (MacNeil et al., 2018). Study 1 was the 
first to report a low prevalence of known risk factors among IMD cases in England. 
 
Study 2 presented MATS coverage estimates for 2014-15 MenB isolates in the UK and 




08 data. The study estimated the coverage of the vaccine as well as stratifying these 
estimates by age group, geographical region, disease severity and outcome. While the 
number of MenB cases in 2014-15 was nearly half of that in 2007-08, this study showed 
MATS coverage declined by 7% and the number of isolates covered by more than one 
antigen dropped by 15% (Parikh et al., 2017). These findings seem to be at odds with 
evidence using human SBA (hSBA) data of 4CMenB-vaccinated adolescents which 
reported that a third had no bactericidal antibodies against the outbreak strain, even 
though this strain was predicted by MATS to be covered on fHbp and NHBA 
components (Basta et al., 2016). It is widely acknowledged that MATS results should be 
treated with caution as is thought to be a conservative estimate when compared to 
serum bactericidal antibodies (SBA) (Frosi et al., 2013).This is because small amounts 
of antibody against a few antigens can act synergistically (Giuliani et al., 2010). 
Furthermore, estimates of vaccine antigen coverage, as based on the measurement of 
antigen in antibody binding assays are designed to quantify the antigen expressed by 
the meningococcal isolate rather than directly measuring the antibody response of the 
vaccinated individual (Feavers and Maiden, 2017). 
 
The findings in Study 2 showed that the year before the introduction of 4CMenB, a third 
of circulating MenB strains in the UK would not be covered by the vaccine. This aligned 
with results from another study using the Bexsero Antigen Sequence Type (BAST) 
scheme, a genotype-phenotype modelling system, which also predicted 66% coverage 
for MenB isolates in the UK and Ireland between 2010-14 (Brehony et al., 2016). 
However, using clonal complex as a proxy for predicting MATS positivity, as BAST 
does, has been shown to be unreliable, due to the dynamic antigen expression within 
strains, within clonal complexes or both (Vogel et al., 2013; Abad et al., 2016). A 
downfall of MATS and BAST methods are that they are limited by their requirement for 
isolates from culture-confirmed cases of IMD. This could be an ongoing problem as 
work has shown that only about half of all confirmed cases, across all age groups, in 
England are confirmed by culture (Parikh et al., 2018). As a potential way to increase 
the amount of samples to estimate 4CMenB strain coverage, Muzzi and colleagues 




purely genetic approach and thus can be performed on non-culture specimens as well. 
The gMATS method found a predicted coverage of 72-73% in England and Wales, 
which underestimated hSBA estimates (Frosi et al., 2013) and the first VE estimates for 
England (Parikh et al., 2016) but is higher than later VE estimates in England (Ladhani 
et al., 2020). 
 
The potential of 4CMenB to protect against MenW disease has been shown (Ladhani 
et al., 2016). Study 3 explored the potential number of infant MenW cases that could be 
averted through the national 4CMenB vaccination campaign. The second highest 
burden of IMD cases in infants in England is caused by MenW (Ladhani et al., 2015; 
Parikh et al., 2018). Study 3 suggested that a large number of cases may be averted in 
infants as the vaccine has been shown to elicit antibodies against the MenW: cc11 
causing most disease in this age group. The real-world estimates on VE and impact on 
MenW disease in England are currently being undertaken. 
 
3.2. Estimates on the effectiveness and impact of the 4CMenB vaccine 
in England 
 
Impact and effectiveness of 4CMenB has been shown elsewhere. During a local 
outbreak of MenB disease in Quebec, Canada in 2014, 82% of 59,000 eligible 
individuals aged two months to 20 years of age were immunized, no cases of IMD arose 
in vaccinated persons and their analysis showed a 78% reduction in IMD after this 
vaccination campaign (Flacco et al., 2018). 4CMenB has been used in multiple 
university outbreaks, in thousands of adolescents, yet none have reported additional 
cases (McNamara et al., 2015; Basta et al., 2016; Biswas, 2016; Duffy et al., 2017; 
Thabuis et al., 2018). 
 
The studies in this chapter were the first to show a reduced two-dose infant priming 
schedule of the 4CMenB vaccine was effective in preventing MenB disease in infants 
aged younger than 12 months and showed that cases of MenB halved in vaccine 
eligible infants during the first 10 months of the programme in England. These findings 




will provide evidence for updating the vaccine’s licensure from a three dose to a two-
dose priming schedule. These studies also provided the first real-world evidence of the 
effectiveness of 4CMenB in preventing MenB disease 3 years after its introduction into 
the U.K national infant immunisation programme and showed that the 12-month booster 
protected against MenB disease for at least 2 years, which was reassuring given the 
initial concerns about rapidly waning levels of antibodies (Martin and Snape, 2013). 
These findings are particularly important as the highest burden of MenB disease in 
England is before three years of age (Ladhani et al., 2016). 
 
3.3. Epidemiology of IMD in vulnerable populations 
 
 
Study 5 demonstrated the first 4CMenB vaccine failure in a young adult on long-term 
terminal complement inhibitor therapy, Eculizumab. An unwanted complication of this 
therapy is an increased risk of infection with encapsulated bacteria, particularly 
Neisseria meningitidis (Nester and Thomas, 2012). Although individuals with 
complement deficiency are at an increased risk, it seems they generally experience less 
severe disease with low case fatality (Figueroa and Densen, 1991). One explanation 
suggests there may be a lower release of endotoxin from the bacterial surface when a 
terminal complement pathway is not intact (Figueroa and Densen, 1991). However, 
more recent research showed that while Eculizumab inhibits bactericidal activity via 
complement-mediated serum, it does not block opsonophagocytic activity, which does 
not require the terminal complement pathway to function and thus this may help prevent 
severe disease (Findlow et al., 2015). There is also potential hope in a new drug (ACH-
4471) that may be able to be used in place of Eculizumab that carries less of a risk of 
developing IMD in patients on this treatment (Ellis-Pegler et al., 2016). Other work has 
since been published that aligns with the findings in Study 5 and describes patients with 
inherited and acquired complement deficiency who developed IMD in England over a 
decade. It showed that in England, complement deficiency is rare among IMD cases, 
these findings included inherited disorders of the late complement pathway, immune-
mediated disorders associated with low complement levels and patients on Eculizumab 





Study 7 looked at another group at an increased risk for invasive disease, those who 
initially present with primary meningococcal conjunctivitis (PMC). It was well 
documented that those initially presenting with PMC are at an increased risk of 
developing systemic disease. This study showed a clear gap in consistent clinical 
recommendations for the treatment of these cases while confirming that current UK 
public health guidelines on the management of these cases is rooted in firm evidence. A 
recent study also identified resistant meningococcal conjunctivitis in people returning 
from Mecca (Zumla and Memish, 2019), which provides additional evidence for 
highlighting the urgent need to review currently recommended prophylactic measures, 
maybe particularly for Hajj pilgrims, in an effort to best prevent cases of systemic IMD. 
 
Study 8 showed, for the first time, the unusual finding of a decreased risk of IMD 
amongst pregnant women when compared to non-pregnant women of a comparable 
age. Pregnancy is often considered a general condition of immunosuppression and 
other studies have shown pregnant women to be at an increased risk for a number of 
other bacterial infections including non-typeable Haemophilus influenzae (ntHi) disease 
(Collins et al., 2014) listeriosis (Mylonakis et al., 2002; Goulet et al., 2012; Pouillot et al., 
2012) and invasive group B streptococcus (GBS) disease (Deutscher et al., 2011). This 
increased risk has been thought to be related to the placental immune response and its 
tropism for specific pathogens that are suspected to affect the pregnant woman’s 
susceptibility to and severity of certain infectious diseases (Mor and Cardenas, 2010). A 
possible reason of why pregnant women may be at a lower risk for IMD may be due to 
changes in their social interaction with others, resulting in lower exposure to 
meningococcal carriers (Parikh et al., 2019). Study 8 and the included reviewed 
literature still showed that if contracted during pregnancy, IMD can still be a severe 
infection and additionally clinicians should still be aware of the ability of meningococci to 
colonize the urogenital and anal tracts (Sunderland et al., 1972; Givan et al., 1977) 
(Givan et al, 1977; Sunderland et al, 1972) which is then still poses a risk of 
transmission during sexual contact and childbirth. A very recent study showed 




implications for both antimicrobial resistance and an increase in sexual transmission of 





This collection of studies has shown the importance and impact of the 4CMenB vaccine 
on the epidemiology of MenB disease in England. The multidisciplinary surveillance 
system in England allowed for the collection of high-quality national data which was 
used to generate information on IMD case numbers, disease characteristics, estimate 
the impact and effectiveness of 4CMenB in vaccinated populations in England and 
identify vaccine failures. These studies established both epidemiological and molecular 
baselines of MenB disease prior to the introduction of 4CMenB in late 2015. The two 
studies on the impact and effectiveness at 10 months and three years post introduction 
were the first to show sustained impact on MenB disease and real-world vaccine 
effectiveness. Furthermore, this work highlighted the need for increased awareness in 
health professionals responsible for the care of complement deficient patients and 
potential failure to illicit immune responses to 4CMenB vaccine. These studies also 
identified gaps in clear clinical recommendations in the treatment of individuals with 
primary meningococcal conjunctivitis, who are at an increased risk for systemic disease. 




6. Future work 
 
As genomic analyses of meningococci are a routine component of enhanced national 
surveillance data in England, there is a breadth of information available on isolates of 
IMD. However, it is still not fully understood why disease presentation and severity 
varies so widely from person to person, thus there is a need for genome comparison 
studies between human and bacterial genomes, in an effort to elucidate potential 
explanations for these variations and use these potential findings to better tailor 
recommendations and prophylactic efforts to protect those at an increased risk for 




surveillance protocol to encompass the retrospective collection of information on IMD 
outcomes and sequelae in children aged less than five years (from 01 September 2015 
to present). This information provides the possibility to compare disease outcomes and 
recorded sequelae in vaccinated and unvaccinated children to understand if the vaccine 
is providing protection against severe disease. Currently, there are no 
recommendations for individuals with malignancies to receive vaccination as part of a 
risk group. Data from epidemiological questionnaires completed by local health 
protection teams also provides a potential to explore risk amongst individuals with 
reported malignancies and/or on immunosuppressive treatments. There are also early 
data to suggest 4CMenB may cross-react and offer protection against infection with 
Neisseria gonorrhoeae (Régnier and Huels, 2014), a bacteria famously associated with 
antibiotic resistance, further studies into the vaccine’s effectiveness and impact against 
this disease could provide huge benefits to nearly 98 million new cases of  
 
gonorrhea occurring annually . 
 
 
In 2017, the European Medicines Agency (EMA) licensed rLP2086 (Trumenba), a fHbp 
vaccine for active immunisation to prevent MenB disease in individuals at least ten 
years of age. This vaccine is different to 4CMenB in that Trumenba contains a variant 
from each of the two identified subfamilies of the meningococcal surface protein fHbp . 
The protein, fHbp is expressed by the majority of invasive meningococci and in an 
extensive program of clinical trials in adolescents and young adults, it was 
demonstrated that a two-dose or three-dose series of Trumenba elicits a strong 
immune response against a range of MenB test strains selected to be representative of 
strains prevalent in Europe and the USA . Population based data is required to estimate 
the true effectiveness of the vaccine and as it is not licensed for use in children less 
than 10 years of age, the protection of infants will rely on the ability of Trumenba to 
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